
Aim Metastases of unknown origin (MUO) remain a diagnostic challenge, with identification of the primary tumor closely tied to treatment planning and survival. This study aimed to evaluate the diagnostic performance of 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT) in detecting the primary tumor in MUO patients. Method This cross-sectional study included 73 patients with MUO who underwent 18 F-FDG PET/CT at the Department of Clinical Oncology and Nuclear Medicine, Assiut University Hospitals, between November 2023 and December 2025. PET/CT findings were correlated with histopathological or clinical-radiological follow-up to classify results as true/false positive/negative. Result Median age was 64 years (37 males, 36 females). PET/CT suggested a primary tumor site in 76.7% (56/73) of patients. PET/CT correctly localized the primary in 50 patients (true positive), was falsely positive in 6, falsely negative in 2, and correctly excluded a detectable primary in 15 (true negative). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 96.15, 71.4, 89.3, 88.2, and ~89%, respectively. Lung was the most common identified primary (20%), followed by lymphoma and ovarian cancer (10% each). PET/CT altered tumor, node, metastasis staging or diagnosis in 10 patients (13.7%): 3 (4.1%) were upstaged to M1b, 2 (2.7%) were downstaged to M0, and 5 (6.8%) were reclassified as nonmalignant based on PET/CT findings. Conclusion 18 F-FDG PET/CT is a high-yield, single-step imaging tool for evaluating MUO, showing a primary tumor detection rate and diagnostic accuracy favorable relative to previously published series, and significantly influencing clinical management strategies. Given the modest sample size and heterogeneous reference standard, these findings should be regarded as preliminary pending validation in larger, multicenter cohorts.
Objective The study aimed to assess whether quantitative fluorine-18 fluorodeoxyglucose ([ 18 F]FDG) PET features provide stable incremental predictive information beyond maximum axial computed tomography (CT) tumor diameter for pathological T category ≥2 in resected nonsmall cell lung cancer (NSCLC) presenting as solitary pulmonary nodules. Methods We retrospectively analyzed 180 consecutive resected solitary pulmonary nodules. The primary cohort comprised 118 NSCLCs with pathological T category, including 33 pathological T category ≥ 2 cases. PET features from 41% maximum standardized uptake value and fixed standardized uptake value 2.5 segmentations were evaluated alongside CT diameter. CT interobserver reproducibility and pathological determinants of pathological T category ≥ 2 were assessed. Performance was evaluated using bootstrap confidence intervals (CIs), repeated five-fold cross-validation, calibration, Brier score, and nested ridge regression. Results CT diameter was associated with pathological T category ≥ 2 (odds ratio per 5 mm = 1.95; 95% CI = 1.31–2.93; area under the receiver operating characteristic curve (AUC) = 0.684) and showed excellent reproducibility (intraclass correlation coefficient = 0.966; 95% CI = 0.953–0.976). Twenty-five of 33 events (75.8%) were nonsize-driven, including 22 with visceral pleural invasion. CT diameter and metabolic tumor volume (MTV) at the 41% threshold were strongly but not redundantly correlated ( ρ = 0.783). CT+MTV41% yielded apparent AUC 0.687 (ΔAUC 0.003; 95% CI = −0.004 to 0.010) and cross-validated AUC 0.656 versus 0.672 for CT alone. CT + mean standardized uptake value 2.5 achieved cross-validated AUC 0.677. Penalized models likewise showed no stable improvement after internal validation. Conclusion Quantitative PET features were associated with pathological extension, but no stable incremental predictive value beyond CT tumor diameter was demonstrated in this cohort. Modest additional value cannot be excluded, and external validation is warranted.
OBJECTIVE The study aimed to assess whether baseline fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT)-derived CT radiomics adds predictive value to clinicopathological biomarkers and PET metabolic assessment for pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer. METHODS This retrospective study included 104 patients with stage I-III breast cancer who underwent baseline 18F-FDG PET/CT, NAC, and surgery. Clinicopathological variables and tumor maximum standardized uptake value (SUVmax) were recorded; 107 CT radiomic features were extracted using PyRadiomics. Clinical, Metabolic, Radiomics, and Combined models were developed using L2-regularized logistic regression and evaluated by nested five-fold cross-validation. Discrimination, calibration, and decision curve analysis were assessed; 95% confidence intervals (CIs) were estimated using 1000 bootstrap resamples of pooled out-of-fold predictions. RESULTS Forty-six patients (44.2%) achieved pCR. Area under the curves (AUCs) were 0.784 (95% CI: 0.686-0.875) for Clinical, 0.595 (0.470-0.704) for Metabolic, and 0.636 (0.526-0.739) for Radiomics models. The Combined model had the highest numerical AUC (0.797; 95% CI: 0.705-0.880), with accuracy 0.731, sensitivity 0.630, specificity 0.810, and F1-score 0.674. CONCLUSION Combining CT radiomics and SUVmax with clinicopathological biomarkers yielded the highest numerical discrimination for pCR, but improvement over the Clinical model was modest. Larger multicenter external validation is needed before clinical implementation.
AIM The study aimed to evaluate whether there is any correlation between metabolic parameters derived from baseline fluorine-18 fluorodeoxyglucose (F-18 FDG) PET-computed tomography (CT) and programmed death-ligand 1 (PDL-1) expression in patients with metastatic non-small cell lung carcinoma (NSCLC). METHODS 33 biopsy-proven metastatic NSCLC patients were included. On immunohistochemistry, a tumor proportion score (TPS) of ≥1% was considered PDL-1 positive, while a TPS of <1% was considered negative. Metabolic parameters of the F-18 FDG PET-CT scan were obtained by drawing a region of interest around the index lung lesion. Data were analyzed using Shapiro-Wilk test of normality, unpaired t-tests/Mann-Whitney U test, Spearman's rank correlation, Youden's index, and receiver operator characteristic (ROC) analysis. RESULTS Spearman's correlation analysis demonstrated a moderate positive correlation (r = 0.466, P = 0.0063) between maximum standardized uptake value (SUVmax) and overall PDL-1 expression. Similarly, a moderate positive correlation was noted between SUVmax and tumors with positive PDL-1 expression (r = 0.643, P = 0.013), with mean SUVmax in PD-L1-positive tumors being significantly higher (P = 0.032). The ROC curve analysis yielded a cutoff value of SUVmax >18 to differentiate between PDL-1-positive and -negative tumors with a sensitivity of 57.1% and specificity of 89.5%. Total lesion glycolysis (TLG) and metabolic tumor volume (MTV) showed no significant association with PDL-1 expression (P = 0.58 and P = 0.88, respectively). CONCLUSION The study indicates that SUVmax has the potential to be used as a noninvasive biomarker for predicting PDL-1 expression in NSCLC. No significant difference was noted in the median MTV and TLG values between the PDL-1-positive and -negative groups.
This study aimed to evaluate cerebral amyloid-PET findings in adults with obstructive sleep apnoea (OSA), account for overlapping cohorts, and quantify global cortical amyloid burden where outcomes were commensurable. PubMed, Scopus, and Web of Science were searched from inception to 17 July 2026 for adult human studies relating OSA or sleep-disordered breathing to cerebral amyloid PET. One estimate per independent data source was retained. The second author independently verified eligibility, cohort independence, extracted quantitative data, and risk-of-bias judgements for all reports entering any quantitative model. Global outcomes were pooled as Hedges’ g using restricted maximum-likelihood random-effects models with modified Hartung-Knapp confidence intervals. Fifteen reports representing 12 independent data sources were included. Tracers, reference regions, partial-volume correction, OSA ascertainment, and cognitive status varied substantially. Three global-outcome cohorts of cognitively unimpaired participants ( n = 291) yielded g = 0.42 (95% confidence interval, −0.14 to 0.99; I 2 = 0%). In a secondary analysis, adding one cohort with established Alzheimer’s disease yielded g = 0.54 (95% confidence interval, 0.22–0.86; n = 471; I 2 = 0%). A sensitivity model adding one selected regional 11C-PiB estimate yielded g = 0.47 (95% confidence interval, 0.17–0.78). In a secondary analysis combining cognitively unimpaired adults and patients with established Alzheimer’s disease, OSA was associated with higher global cerebral amyloid-PET burden. However, the primary evidence in cognitively unimpaired adults remains imprecise, and longitudinal studies do not consistently demonstrate an association between conventional OSA severity and amyloid accumulation.